Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | beta-site APP-cleaving enzyme 1 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | memapsin-2 (A01 family) | Get druggable targets OG5_135830 | All targets in OG5_135830 |
Schistosoma japonicum | ko:K07747 beta-site APP-cleaving enzyme 2 (memapsin 1) [EC3.4.23.45], putative | Get druggable targets OG5_135830 | All targets in OG5_135830 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | plasmepsin VII | beta-site APP-cleaving enzyme 1 | 401 aa | 352 aa | 21.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | plasmepsin VI | 0.0021 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0021 | 0 | 0.5 |
Loa Loa (eye worm) | aspartyl protease 6 | 0.0021 | 0 | 0.5 |
Plasmodium vivax | aspartyl protease, putative | 0.0021 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0021 | 0 | 0.5 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0021 | 0 | 0.5 |
Plasmodium vivax | aspartyl protease, putative | 0.0021 | 0 | 0.5 |
Toxoplasma gondii | aspartyl protease ASP1 | 0.0021 | 0 | 0.5 |
Plasmodium vivax | aspartyl protease, putative | 0.0021 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin V | 0.0021 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin IX | 0.0021 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin VII | 0.0021 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin I | 0.0021 | 0 | 0.5 |
Brugia malayi | Eukaryotic aspartyl protease family protein | 0.0021 | 0 | 0.5 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0021 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin X | 0.0021 | 0 | 0.5 |
Onchocerca volvulus | 0.0317 | 0.5912 | 1 | |
Brugia malayi | aspartic protease BmAsp-1, identical | 0.0021 | 0 | 0.5 |
Toxoplasma gondii | eukaryotic aspartyl protease superfamily protein | 0.0021 | 0 | 0.5 |
Toxoplasma gondii | aspartyl proteinase (eimepsin), putative | 0.0021 | 0 | 0.5 |
Trichomonas vaginalis | Clan AA, family A1, cathepsin D-like aspartic peptidase | 0.0021 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin IV | 0.0021 | 0 | 0.5 |
Toxoplasma gondii | aspartyl protease | 0.0021 | 0 | 0.5 |
Plasmodium vivax | plasmepsin IV, putative | 0.0021 | 0 | 0.5 |
Echinococcus multilocularis | cathepsin d (lysosomal aspartyl protease) | 0.0021 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin VIII, putative | 0.0021 | 0 | 0.5 |
Echinococcus granulosus | cathepsin d lysosomal aspartyl protease | 0.0021 | 0 | 0.5 |
Brugia malayi | aspartic protease BmAsp-2, identical | 0.0021 | 0 | 0.5 |
Toxoplasma gondii | aspartyl protease ASP3 | 0.0021 | 0 | 0.5 |
Brugia malayi | Pepsin A precursor | 0.0021 | 0 | 0.5 |
Loa Loa (eye worm) | aspartic protease BmAsp-2 | 0.0021 | 0 | 0.5 |
Brugia malayi | hypothetical protein | 0.0021 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin III | 0.0021 | 0 | 0.5 |
Loa Loa (eye worm) | aspartic protease BmAsp-1 | 0.0021 | 0 | 0.5 |
Plasmodium vivax | plasmepsin V, putative | 0.0021 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin II | 0.0021 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0021 | 0 | 0.5 |
Brugia malayi | hypothetical protein | 0.0021 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 68 nM | Inhibition of BACE-1 in human HEK293 cells overexpressing APP 695 swedish mutation assessed as inhibition of amyloid beta (1 to 40) production by immunoprecipitation assay | ChEMBL. | 21974952 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.